Projet MIPrecise (Horizon Europe, appel à projets 2024)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : SIGNED

Cancer treatment outcomes vary widely due to inequalities in access to tests, drugs and the need for regular visits to specialist clinics. Many limitations can be addressed by developing more sensitive and robust tests for underexploited cancer biomarkers that can detect cancer sooner, be deployed in local clinics and simplify sample shipment and storage. Such tests will improve health outcomes, and also reduce the substantial environmental impact of biological reagent manufacture and patient travel. MIPrecise is an innovative and integrative network for training of doctoral candidates (DCs) that aims to address these challenges by re-engineering the diagnostic development and delivery pipeline through use of inexpensive, highly stable imprinted polymers. Training a new generation of doctoral scientists in methods that can develop and transition the novel diagnostic and monitoring platforms is crucial, for sustainable development and future impact for cancer patients. Through four work packages MIPrecise will make progress related to the following cancer relevant topics:  - Assays for guiding personalized therapies based on kinase inhibitors - Robust assays and home based sampling for small cell lung cancer - Discovery of new biomarkers for more precise cancer diagnostics - Fast and sensitive liquid biopsies for assessment of tumour aggresiveness  The project will give 13 DCs a first-class interdisciplinary and intersectorial training program that combines scientific excellence with important transferable, business and entrepreneurial skills. This meets needs for highly skilled researchers supporting a competitive MedTech sector in Europe. 12 leading groups in the field of molecular imprinting, smart materials, proteomics, single cell analysis and clinical diagnostics at 8 universities, 1 research institute and 3 companies will form an inter-disciplinary expert network to develop disruptive greener technologies to address inequalities in cancer care.

Mots clés : sustainable healthcare, molecular imprinting, posttranslational modification, phosphorylation, diagnostic assay, home based sample collection

Participants :
- Proteome sciences r&d gmbh & co. kg (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 290272.32 €
- Resyn biosciences pty ltd (Afrique du Sud) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université technique du Danemark (Danemark) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 335890.08 €
- Federal Institute For Materials Research and Testing (Allemagne) — Partner, beneficiary, Recherche, subvention : 290272.32 €
- Linnaeus University (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 324630.0 €
- Université du Danemark du Sud (Danemark) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 671780.16 €
- Université de Pavie (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281755.08 €
- Université d'Oslo (Norvège) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 339932.16 €
- Université de Strathclyde (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 697476.24 €
- Université d'Umeå (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 324630.0 €
- Capitainer ab (Suède) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ceratium bv (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Malmö (Suède) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 649260.0 €